Research Article

Promoter Hypermethylation and Suppression of Glutathione Peroxidase 3 Are Associated with Inflammatory Breast Carcinogenesis

Mona M. Mohamed,1 Salwa Sabet,1 Dun-Fa Peng,2 M. Akram Nouh,3 Mohamed El-Shinawi,4 and Wael El-Rifai2

1 Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt
2 Department of Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA
3 Department of Pathology, National Cancer Institute, Cairo University, Giza 12613, Egypt
4 Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt

Correspondence should be addressed to Mona M. Mohamed; mmostafa@sci.cu.edu.eg

Received 25 November 2013; Revised 22 January 2014; Accepted 30 January 2014; Published 20 March 2014

Academic Editor: Jeannette Vasquez-Vivar

Copyright © 2014 Mona M. Mohamed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reactive oxygen species (ROS) play a crucial role in breast cancer initiation, promotion, and progression. Inhibition of antioxidant enzymes that remove ROS was found to accelerate cancer growth. Studies showed that inhibition of glutathione peroxidase-3 (GPX3) was associated with cancer progression. Although the role of GPX3 has been studied in different cancer types, its role in breast cancer and its epigenetic regulation have not yet been investigated. The aim of the present study was to investigate GPX3 expression and epigenetic regulation in carcinoma tissues of breast cancer patients’ in comparison to normal breast tissues. Furthermore, we compared GPX3 level of expression and methylation status in aggressive phenotype inflammatory breast cancer (IBC) versus non-IBC invasive ductal carcinoma (IDC). We found that GPX3 mRNA and protein expression levels were downregulated in the carcinoma tissues of IBC compared to non-IBC. However, we did not detect significant correlation between GPX3 and patients’ clinical-pathological prosperities. Promoter hypermethylation of GPX3 gene was detected in carcinoma tissues not normal breast tissues. In addition, IBC carcinoma tissues showed a significant increase in the promoter hypermethylation of GPX3 gene compared to non-IBC. Our results propose that downregulation of GPX3 in IBC may play a role in the disease progression.

1. Introduction

The breast tumor microenvironment is characterized by the release of endogenous reactive oxygen species (ROS) that resulted from accumulation of different metabolic and pathological changes such as glucose deprivation, steroid hormones metabolism by lactoperoxidase [1], mitochondrial disorder [2], infiltration of macrophages [3], and angiogenesis and reperfusion of blood vessels [4, 5]. Removal of ROS from tissues is achieved by the family of glutathione peroxidases (GPXs) (Enzyme Commission number 1.11.1.9) expressed cytoplasmically and their expression is tissue specific [6]. GPXs are known to protect cells against oxidative stress by catalyzing the reduction of H2O2, organic hydroperoxide and lipid peroxides by reduced glutathione [6].

Among the family of GPXs, the isoenzyme GPX3 is found to play a crucial role in the removal of ROS and healthy tissue detoxification [6]. In addition, studies showed that expression and activity of GPX3 contribute to prevention of cancer initiation [7, 8]. Paradoxically, GPX3 inhibition is suggested to be associated with different stages of cancer progression including initiation, promotion, and metastasis [6]. GPX3 was found to be downregulated in the plasma of breast, gastric, and colorectal cancer patients [9]. Moreover, GPX3 downregulation was reported in prostate cancer tissues [10], thyroid cancer [11], and esophageal cancer [12, 13]. Promoter
hypermethylation mechanism which is a “frequent event in human cancers” may result in GPX3 gene silencing and inhibition of GPX3 expression [14]. GPX3 promoter hypermethylation and downregulation were detected in prostate cancer [15]; endometrial adenocarcinoma [16]; cervical, thyroid, and lung cancer [17]; head and neck carcinoma [14]; gastric cancer [18]; and multiple myeloma [19]. GPX3 hypermethylation correlates with disease poor prognosis and resistance to chemotherapy in head and neck cancer patients [14] and multiple myeloma [19]. Recently, we found that inactivation of the GPX3 gene by promoter hypermethylation in gastric cancer is associated with high incidence of lymph node metastasis [20].

Inflammatory breast cancer (IBC) is an aggressive and highly metastatic form of breast cancer, most prominent among premenopausal women [21]. IBC is characterized by rapid onset over a period of only weeks to a few months, and among premenopausal women [21]. IBC is characterized by highly metastatic form of breast cancer, most prominent associated with high incidence of lymph nodemetastasis [20]. IBC is characterized by rapid onset over a period of only weeks to a few months, and among premenopausal women [21]. IBC is characterized by highly metastatic form of breast cancer, most prominent associated with high incidence of lymph nodemetastasis [20].

Inflammatory breast cancer (IBC) is an aggressive and highly metastatic form of breast cancer, most prominent among premenopausal women [21]. IBC is characterized by rapid onset over a period of only weeks to a few months, and among premenopausal women [21]. IBC is characterized by highly metastatic form of breast cancer, most prominent associated with high incidence of lymph nodemetastasis [20].

2. Materials and Methods

2.1. Reagents. DNeasy tissue kit was purchased from Qiagen (Valencia, CA, USA). EZ DNA Methylation-Gold Kit was purchased from ZYMO Research (Orange, CA, USA). Dako Antibody Diluent-Reduce Background and Dako Cytomation EnVision+ Dual Link System-HRP (DAB+) kit (catalog number K4065) were purchased from Dako (Carpinteria, CA, USA). Mouse anti-GPX3 monoclonal antibody, Clone 23B1, was purchased from Abcam, Cambridge, MA, USA. Permount was purchased from Fisher Scientific (Fair Lawn, NJ, USA). Unless otherwise stated all other reagents were from Sigma (St. Louis, MO, USA).

2.2. Patients and Tissues. Patients were enrolled from Breast Clinics of Ain Shams University Hospitals, Ain Shams University, Cairo, Egypt, after obtaining the Institutional Review Board (IRB) approval from the ethics committee of Ain Shams University. All patients signed informed consent before participating in the study. Breast cancer diagnosis was achieved by clinical examination, ultrasound, mammography, and biopsy. In the present study, we enrolled 40 women clinically diagnosed with breast cancer. Patients were divided into non-IBC (n = 20) and IBC (n = 20) subgroups. Patients were considered to harbor IBC when they presented with a swollen breast, skin inflammation, and edema as previously described [21]. In addition, 6 normal breast tissue samples donated by healthy volunteers undergoing mammoplasty were used as control.

Tissue samples were collected either from preadjuvant chemotherapy tissue biopsies or during modified radical mastectomy. Tissue samples were divided into two pieces, one snap-frozen at −80°C in RNAlater (Qiagen) and one fixed in 10% neutral buffered formalin and processed for sectioning for routine pathological examination as well as for immunohistochemistry. Pathological data regarding tumor size, tumor grade [28], presence and absence of lymphovascular invasion, and dermal and tumor stromal lymphatic emboli were assessed for routine diagnosis as we described before [21].

2.3. Assessment of mRNA Expression of GPX3 Using Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). We isolated total RNA from frozen breast tissue samples using an RNeasy Mini kit (Qiagen), following the manufacturer’s instructions. Single-stranded cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). We assessed transcription levels of GPX3 in breast cancer samples versus normal tissues (control) from breast of healthy volunteers using qRT-PCR. GPX3 primers were used as we described before (forward 5'-GGCGGG-GACAAAGAGAAGT-3' and reverse 5'-GAGGACGTATTT-GCCAGCAT-3') [20]. Quantitative real-time PCR (qRT-PCR) reactions were carried out using Bio-Rad IQ SYBR GREEN Supermix (Bio-Rad, CA, USA) on iCycler (Bio-Rad, CA, USA), with the threshold cycle number determined by use of iCycler software version 3.0. All samples were run in triplicate, and the threshold cycle (Ct) was determined using the iCycler software and then was averaged. Results were normalized to internal control Hypoxanthine phosphoribosyltransferase-1 (HPRT1) and GPX3 expression fold was calculated according to the formula 2(Rn−Ei)/2(Rn−En) as previously described [29], where Rn is the threshold cycle number for the reference gene observed in the tumor, Ei is the threshold cycle number for the experimental gene observed in the tumor, Rn is the threshold cycle number for the reference gene observed in the normal samples, and En is the threshold cycle number for the reference gene observed in the tumor. Rn and En values were calculated as an average of the 6 normal samples. For all primary BACs, the gene was considered to be downregulated if the mRNA expression fold was ≤0.5 in comparison with the normal samples [20].

2.4. Immunohistochemistry. Tissue sections of 5 μm thickness were prepared from paraffin blocks of breast carcinoma and normal breast tissues and stained with hematoxylin and eosin to select sections suitable for immunostaining and scoring. Tissue sections were first deparaffinized and
rehydrated through graded concentrations of ethanol. For antigen retrieval, slides were incubated in citrate buffer (pH 6.0) in a water bath for 1h at 99°C. Slides were cooled by incubation in Tris-buffered saline (TBS: 0.05 mol/L Tris-HCl, pH 7.6, 0.15 mol/L NaCl, and 0.05% Tween 20) for 20 min. Endogenous peroxidase activity was blocked by using Dako Dual Endogenous Enzyme Block for 10 min. For immunohistochemical stain of GPX3, tissue sections were incubated for 1h at room temperature with the primary antibody mouse anti-GPX3 (mouse anti-GPX3 monoclonal antibody, Clone 23B1, Abcam). The monoclonal antibody was diluted 1: 100 in Dako Antibody Diluent-Reduce Background product (DAKO). Detection was carried out by incubating sections with 100 µL of Horseradish Peroxidase (HRP) Rabbit/Mouse (EnVision+ Dual Link System-HRP diamobenzidine (DAB+)) for 45 min. Staining was achieved by adding 100 µL of DAB+ diluted 1: 50 in substrate buffer [EnVision+ Dual Link System-HRP (DAB+)]. Staining was progressed for 15 min until the development of brown color. Nuclei were counterstained with hematoxylin, rinsed in PBS, and mounted using Permount for microscopic examination. Negative control slides were run in parallel with each marker where the primary antibody is replaced by PBS. The level of expression of GPX3 protein was scored according to both the intensity and the positivity of the stain of the cells within the entire slide: negative, no immunostaining is observed; score (+), less than 10% of cells showed no or weak staining; score (++), 10–50% of cells showed moderate to strong staining; and score (+++), more than 50% of cells showed strong staining [21].

2.5. DNA Extraction from Fresh Tissue and Identification of CpG Islands in the Promoter Region of GPX3 Gene. Genomic DNA was extracted from 25 mg of fresh tissue of biopsy or modified radical mastectomy using DNeasy tissue kit Qiagen. In the last step of the protocol, DNA was eluted in 200 µL elution buffer. We used University of California’s (UCSC) Genome Browser website (http://genome.ucsc.edu/) to obtain DNA sequences around the promoter region. Identified sequences were confirmed to be identical to that from the DBTSS (database of transcriptional start sites, http://dbtss.hgc.jp/) as described [29]. The CpG island in the promoter region of GPX3 was defined using CpG island searcher online tool (http://www.uscnorris.com/cpgislands2/cpg.aspx).

2.6. DNA Bisulfite Treatment and Methylation-Specific PCR (MSP). Bisulfite modification of the purified DNA was achieved by using an EZ DNA methylation-Gold kit (ZYMO Research, Orange, CA, USA) following the manufacturer’s instructions. We used 1 µg of extracted genomic DNA of each sample from normal breast tissue samples, IBC and non-IBC breast carcinoma tissue samples [12, 29]. The bisulfite treated DNA was subjected to MSP in a final reaction of 50 µL. We designed primers for MSP targeting CpG-rich promoter region using online software “MethPrimer” (http://www.urogene.org/methprimer/). The forward and reverse primers used for methylated GPX3 were 5’- GTTGAGGGTAAGTCGCCGTTCC-3’ and 5’- GTCCGTCTAAAAATATCCGACG-3’ and those for unmethylated GPX3 were 5’- GAGTTGAGGTTAGGTTGTTGTGTTTGT-3’ and 5’- CCATCCATC- TAAAATATCCACACT-3’. PCR mixture included the Platinum PCR SuperMix High Fidelity (Invitrogen, Carlsbad, CA, USA) and the program was adjusted as follows: initial denaturation at 94°C for 5 min, then 35 cycles consisting each of 94°C for 1 min, annealing at 54°C for 1 min, and finally extension at 72°C for 1 min. PCR products were subjected to electrophoresis on 1.5% agarose gel using GelRed nucleic acid stain (Biotium, Hayward, CA, USA) and amplified DNA was visualized by 300 nm transillumination. For quantitative analysis, visualized bands of the agarose gel were analyzed by Image (National Institutes of Health, Bethesda, MA, USA) software. For each carcinoma tissue specimen, the band intensity of the methylated and unmethylated MSP products was quantified and normalized against gel background as described elsewhere [30].

2.7. Statistical Analysis. The data was analyzed using SPSS software version 16.0. Differences were evaluated by Student’s t-test and Fisher’s exact test. P < 0.05 was considered as statistically significant.

3. Results

3.1. Clinical and Pathological Features of IBC and Non-IBC Patients. The clinical and pathological features of non-IBC and IBC patients are presented in Table 1. All of IBC patients were premenopausal one decade younger than non-IBC patients (P < 0.001). Statistical analysis revealed that IBC patients showed a significant higher incidence (P < 0.01) of positive metastatic lymph nodes compared to non-IBC patients. In addition, a significant difference (P < 0.001) in lymphovascular invasion and dermal lymphatic emboli was highly detected in IBC versus non-IBC patients tissue sections.

3.2. Downregulation of the GPX3 Protein Expression in Breast Carcinoma Tissue. Level of expression of GPX3 protein was assessed in normal and carcinoma breast tissues using IHC. GPX3 expression staining results were scored for the positivity and intensity (Table 2). Statistical analysis, using the Chi-square test, revealed that normal breast tissues express significantly high level of GPX3 protein (Figure 1(a)) compared to breast carcinoma tissues of non-IBC (Figure 1(b)) and IBC (Figure 1(c)) patients (P = 0.001 and P < 0.001, resp.). In addition, non-IBC tissues showed a significant increase (P = 0.043) in the level of expression of GPX3 as compared to those of IBC patients.

3.3. Suppression of GPX3 mRNA Expression in IBC Carcinoma Tissue Samples. Inhibition of GPX3 protein expression in the carcinoma tissues of breast cancer patients was confirmed at mRNA level by using qRT-PCR. We found that the level of GPX3 mRNA expression in normal breast tissues was significantly higher than that in breast carcinoma tissue.
### Table 1: Patients' clinical and pathological data.

| Characteristics                      | Non-IBC       | IBC            | P value |
|--------------------------------------|---------------|----------------|---------|
|                                      | n = 20 (%)    | n = 20 (%)     |         |
| **Age**                              |               |                |         |
| Mean ± SE                            | 54.35 ± 2.1   | 40.55 ± 1.7    | <0.001* |
| ≤ 50                                 | 7 (35)        | 18 (90)        |         |
| > 50                                 | 13 (65)       | 2 (10)         |         |
| **Tumor size**                       |               |                |         |
| Mean ± SE                            | 5.12 ± 0.5    | 7.08 ± 0.6     | >0.05   |
| ≤ 2 cm                               | 1 (5)         | 0              |         |
| > 2 cm                               | 19 (95)       | 18 (90)        |         |
| **Tumor grade**                      |               |                |         |
| G2                                   | 15 (75)       | 14 (70)        | >0.05   |
| G3                                   | 5 (25)        | 6 (30)         |         |
| **Lymph node status**                |               |                |         |
| Positive                             | 17 (85)       | 18 (90)        | >0.05   |
| Negative                             | 3 (15)        | 0              |         |
| **Number of lymph nodes**            |               |                |         |
| ≤ 6                                  | 16 (80)       | 6 (33.3)       | <0.01*  |
| > 6                                  | 4 (20)        | 12 (66.7)      |         |
| **Lymphovascular invasion**          |               |                |         |
| Positive                             | 2 (10)        | 14 (70)        | <0.001* |
| Negative                             | 18 (90)       | 6 (30)         |         |
| **Dermal lymphatic emboli**          |               |                |         |
| Positive                             | 2 (10)        | 18 (90)        | <0.001* |
| Negative                             | 18 (90)       | 2 (10)         |         |
| **ER status**                        |               |                |         |
| Positive                             | 7 (35)        | 6 (30)         | >0.05   |
| Negative                             | 13 (65)       | 14 (70)        |         |
| **PR status**                        |               |                |         |
| Positive                             | 9 (45)        | 7 (35)         | >0.05   |
| Negative                             | 11 (55)       | 13 (65)        |         |
| **HER-2 status**                     |               |                |         |
| Positive                             | 2 (10)        | 4 (20)         | >0.05   |
| Negative                             | 18 (90)       | 16 (80)        |         |

* Significant P value calculated by Student's t-test.
** n = 18 in IBC patients.

### Table 2: Scoring of GPX3 expression in normal, non-IBC, and IBC breast tissues.

| Score | Normal (n = 6) | Non-IBC (n = 16)* | IBC (n = 16)*<sup>bc</sup> |
|-------|---------------|-------------------|------------------------------|
|       | n (%)         | n (% =)           | n (% =)                      |
| Negative | 0 (0%)       | 5 (31.2%)         | 11 (68.7%)                   |
| +      | 0 (0%)        | 7 (43.8%)         | 3 (18.7%)                    |
| ++     | 3 (50%)       | 4 (25%)           | 2 (12.5%)                    |
| +++    | 3 (50%)       | 0                 | 0                             |

Significant P value calculated by the Chi-square test.

* Significant P value (P = 0.001) when normal tissues were compared to non-IBC tissues.
<sup>b</sup> Significant P value (P < 0.001) when normal tissues were compared to IBC tissues.
<sup>c</sup> Significant P value (P = 0.043) when non-IBC tissues were compared to IBC tissues.

n = number of patients.
samples of non-IBC and IBC ($P = 0.001$ and $P < 0.001$, resp.). We compared the level of mRNA expression of GPX3 in non-IBC and IBC, and our results revealed that mRNA expression level of GPX3 expression in non-IBC carcinoma tissues was statistically significant ($P = 0.036$) higher than that in IBC (Figure 2). Using the Pearson correlation statistical analysis, we did not detect significant correlation between downregulation of GPX3 mRNA and patients clinical-pathological properties (tumor size, tumor grade, and number of axillary metastatic lymph nodes) in non-IBC and IBC patients. However, downregulation of GPX3 in IBC versus non-IBC carcinoma tissues suggests that GPX3 may play a role in IBC disease progression.

3.4. Methylation Profile of GPX3 Promoter Region in Breast Cancer Tissue Samples. Analysis of the promoter region of GPX3 indicated that CpG islands were present within −1000 to +300 bp of the gene. We assessed the GPX3 promoter region methylation in 40 breast cancer tissue samples and 6 normal breast tissue samples. Agarose gel electrophoresis of all normal breast tissues showed only one band corresponding to unmethylated GPX3-MSP products (Figure 3(a)). On the contrary, agarose gel electrophoresis of all GPX3-MSP products breast carcinoma tissue samples showed bands of 200 bp corresponding to both unmethylated (Figure 3(a)) and methylated GPX3-MSP products (Figure 3(b)). The present results showed that GPX3 methylation was detected in breast carcinoma tissues and not in normal breast tissues. Thus, GPX3 promoter methylation is responsible for the downregulation of GPX3 mRNA in breast carcinoma tissues since it was not detected in normal breast tissues. It should be noted that detection of methylated and unmethylated products in some breast carcinoma tissue homogenates may be due to heterogeneous population of breast carcinoma cells and/or the presence of other normal stromal cells from breast tumor microenvironment.

For quantitative analysis, visualized bands of agarose gel were analyzed by ImageJ (National Institutes of Health, Bethesda, MA, USA) software. For each carcinoma tissue specimen, the band intensity of the methylated and unmethylated GPX3-MSP products was quantified and normalized against gel background as described elsewhere [30]. Intensity values of methylated/unmethylated (M/U) ratio for GPX3-MSP products for non-IBC ($n = 20$) and IBC ($n = 20$) patients were analyzed by Student’s $t$-test. Normal breast tissues (N) with an M/U ratio = 0 (no methylated bands were detected from MSP) were assessed as unmethylated. Results revealed a significant increase ($P = 0.04$) in the M/U ratios of GPX3-MSP products in IBC versus non-IBC carcinoma tissues (Figure 3(c)). Significant increase in M/U ratio in IBC versus non-IBC suggests a potential role for GPX3 in IBC disease progression.

4. Discussion

Elevated levels of ROS detected in breast cancer were found to play a crucial role in the disease progression [4]. For instance, carcinoma cells utilize ROS to stimulate cancer cell proliferation, motility, invasion, angiogenesis, and escape of apoptotic mechanism [25]. In addition, ROS augment
GPX3 mRNA is significantly higher in carcinoma tissues of non-IBC patients, the level of expression of IBC carcinoma tissues (\( P < 0.001 \)) than that of IBC. The present results are consistent with other studies which showed downregulation of GPX3 mRNA and protein expression of GPX3 in IBC tissue samples versus non-IBC tissue samples. We did not detect any significant correlation between downregulation of GPX3 mRNA and patients clinical-pathological properties. The present results agree with other studies that showed downregulation of GPX3 in endometrial adenocarcinoma [16] and early invasive breast carcinoma [33] regardless of patients’ clinical and pathological criteria.

IBC is an aggressive phenotype, characterized by high metastatic potential, disease recurrence, and resistance to chemotherapy [36]. Furthermore, recently we found that IBC...
Figure 3: Gel electrophoresis of GPX3 methylation-specific PCR (GPX3-MSP) products. Representative results of MSP using (a) unmethylated primers and (b) methylated primers. M is the DNA marker; lanes N1 and N2 represent normal breast tissues, lanes 1–4 represent non-IBC carcinoma tissues, and lanes 4–8 represent IBC breast carcinoma tissues. (c) Bars represent intensity values of methylated/unmethylated (M/U) ratios as quantified by ImageJ software. Normal breast tissues (n = 6) with an M/U ratio = 0 (no methylated bands were detected from MSP) were recognized as unmethylated. We detected a significant increase (P = 0.04) in the M/U ratio in IBC (n = 20) carcinoma tissues compared to non-IBC (n = 20) carcinoma tissues.
carcinoma tissues are characterized by high infiltration of tumor associated macrophages that enhance carcinoma cells invasion and motility [37]. Interestingly, loss of GPX3 contributes to high infiltration of tumor associated macrophages that support tumor survival in GPX3 knockout mice model [38]. Thus, inhibition of GPX3 in IBC carcinoma tissues may be associated with the high infiltration of macrophages. In addition, quantitative analysis of the band intensities of the corresponding methylated/unmethylated MSP products revealed a significant increase in GPX3 promoter hypermethylation in IBC carcinoma tissues versus non-IBC carcinoma tissues. We assumed that GPX3 may contribute to IBC molecular phenotype.

5. Conclusion

Our results suggest that epigenetic regulation of GPX3 occurred widely in breast cancer tissues compared to normal breast tissues and this may be due to GPX3 promoter hypermethylation in breast cancer cells and not in normal breast tissues. In addition, methylation silencing of GPX3 in IBC may contribute to invasion of IBC carcinoma cells into lymphatic vessels, formation of tumor emboli, and IBC chemoresistance as suggested in other cancers [14, 19]. Further studies to validate the role of GPX3 as a prognostic maker in IBC and identify the mechanisms by which GPX3 is involved in IBC carcinogenesis are essential.

Conflict of Interests

The authors declare that they have no competing interests.

Authors’ Contribution

Mona M. Mohamed and Salwa Sabet contributed equally to this work.

Acknowledgments

This work was supported by Science and Technology Development Funds (STDF), Egypt, Grant no. 408 (Wael El-Rifai and Mona M. Mohamed) and Avon Foundation, USA (Mona M. Mohamed), Awards nos. 02-2007-049 and 02-2009-085b.

References

[1] H. J. Sipe Jr., S. J. Jordan, P. M. Hanna, and R. P. Mason, “The metabolism of 17β-estradiol lactoperoxidase: a possible source of oxidative stress in breast cancer,” Carcinogenesis, vol. 15, no. 11, pp. 2637–2643, 1994.
[2] K. Plak, A. M. Czarnecka, T. Krawczyk, P. Golik, and E. Bartnik, “Breast cancer as a mitochondrial disorder (review),” Oncology Reports, vol. 21, no. 4, pp. 845–851, 2009.
[3] A. M. Fulton and Y. C. Chong, “The role of macrophage-derived TNFs in the induction of sublethal tumor cell DNA damage,” Carcinogenesis, vol. 13, no. 1, pp. 77–81, 1992.
[4] N. S. Brown and R. Bicknell, “Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer,” Breast Cancer Research, vol. 3, no. 5, pp. 323–327, 2001.
[5] D.-H. Kang, “Oxidative stress, DNA damage, and breast cancer,” AACN critical issues, vol. 13, no. 4, pp. 540–549, 2002.
[6] R. Brigelius-Flohé and A. Kipp, “Glutathione peroxidases in different stages of carcinogenesis,” Biochimica et Biophysica Acta, vol. 1790, no. 11, pp. 1555–1568, 2009.
[7] M. P. Rayman, “Selenium in cancer prevention: a review of the evidence and mechanism of action,” Proceedings of the Nutrition Society, vol. 64, no. 4, pp. 527–542, 2005.
[8] J.-Y. Wang, J.-P. Yang, D.-C. Wu, S.-W. Huang, J.-Y. Wu, and S.-H. Huo, “Functional glutathione peroxidase 3 polymorphisms associated with increased risk of Taiwanese patients with gastric cancer,” Clinica Chimica Acta, vol. 411, no. 19–20, pp. 1432–1436, 2010.
[9] Z. Pawlowicz, B. A. Zachara, U. Trafikowska, A. Maciag, E. Marchaluk, and A. Nowicki, “Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer,” Journal of Trace Elements and Electrolytes in Health and Disease, vol. 5, no. 4, pp. 275–277, 1991.
[10] Y. P. Yu, G. Yu, G. Tseng et al., “Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis,” Cancer Research, vol. 67, no. 17, pp. 8043–8050, 2007.
[11] Y. Hasegawa, T. Takano, A. Miyauchi et al., “Decreased expression of glutathione peroxidase mRNA in thyroid anaplastic carcinoma,” Cancer Letters, vol. 182, no. 1, pp. 69–74, 2002.
[12] O.-J. Lee, R. Schneider-Stock, P. A. McChesney et al., “Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett’s tumorigenesis,” Neoplasia, vol. 7, no. 9, pp. 854–861, 2005.
[13] Y. He, Y. Wang, P. Li, S. Zhu, J. Wang, and S. Zhang, “Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma,” Digestive Diseases and Sciences, vol. 56, no. 3, pp. 681–688, 2011.
[14] B. Chen, X. Rao, M. G. House, K. P. Nephew, K. J. Cullen, and Z. Guo, “GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response,” Cancer Letters, vol. 309, no. 1, pp. 37–45, 2011.
[15] D. Lodygin, A. Epathintsev, A. Menssen, J. Diebold, and H. Hermeking, “Functional epigenomics identifies genes frequently silenced in prostate cancer,” Cancer Research, vol. 65, no. 10, pp. 4218–4227, 2005.
[16] E. Falck, S. Karlsson, J. Carlsson, G. Helenius, M. Karlsson, and K. Klinga-Levan, “Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma,” Cancer Cell International, vol. 10, article 46, 2010.
[17] X. Zhang, J.-J. Yang, Y. S. Kim, K.-Y. Kim, W. S. Ahn, and S. Yang, “An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer,” International Journal of Oncology, vol. 36, no. 2, pp. 405–414, 2010.
[18] Y. Qu, S. Dang, and P. Hou, “Gene methylation in gastric cancer,” Clinica Chimica Acta, vol. 424, pp. 53–65, 2013.
[19] M. F. Kaiser, D. C. Johnson, P. Wu et al., “Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma,” Blood, vol. 122, no. 2, pp. 219–226, 2013.
[20] D. F. Peng, T. L. Hu, B. G. Schneider, Z. Chen, Z. K. Xu, and W. El-Rifai, “Silencing of glutathione peroxidase 3 through DNA
hypermethylation is associated with lymph node metastasis in gastric carcinomas," *PLoS ONE*, vol. 7, no. 10, Article ID e46244, 2012.

[21] M. A. Nouh, M. M. Mohamed, M. El-Shinawi et al., "Cathepsin b: a potential prognostic marker for inflammatory breast cancer," *Journal of Translational Medicine*, vol. 9, article 1, 2011.

[22] P. Bonnier, C. Charpin, C. Lejeune et al., "Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?" *International Journal of Cancer*, vol. 62, no. 4, pp. 382–385, 1995.

[23] Y. Gong, "Pathologic aspects of inflammatory breast cancer: part 2. Biologic insights into its aggressive phenotype," *Seminars in Oncology*, vol. 35, no. 1, pp. 33–40, 2008.

[24] M. M. Mohamed, D. Al-Raawi, S. F. Sabet, and M. El-Shinawi, "Inflammatory breast cancer: new factors contribute to disease etiology (Review)," *Journal of Advanced Research*, 2013.

[25] P. Storz, "Reactive oxygen species in tumor progression," *Frontiers in Bioscience*, vol. 10, no. 2, pp. 1881–1896, 2005.

[26] I.-C. Lo, J.-M. Shih, and M. J. Jiang, "Reactive oxygen species and ERK 1/2 mediate monocyte chemotactic protein-1-stimulated smooth muscle cell migration," *Journal of Biomedical Science*, vol. 12, no. 2, pp. 377–388, 2005.

[27] W.-S. Wu, "The signaling mechanism of ROS in tumor progression," *Cancer and Metastasis Reviews*, vol. 25, no. 4, pp. 695–705, 2006.

[28] C. Genestie, B. Zafrañi, B. Asselain et al., "Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems," *Anticancer Research*, vol. 18, no. 1, pp. 571–576, 1998.

[29] D. F. Peng, M. Razvi, H. Chen et al., "DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett’s adenocarcinoma," *Gut*, vol. 58, no. 1, pp. 5–15, 2009.

[30] A. Christians, C. Hartmann, A. Benner et al., "Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma," *PLoS ONE*, vol. 7, no. 3, Article ID e33449, 2012.

[31] Y. J. Hu and A. M. Diamond, "Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium," *Cancer Research*, vol. 63, no. 12, pp. 3347–3351, 2003.

[32] P. Cejas, M. A. García-Cabezas, E. Casado et al., "Phospholipid Hydroperoxide Glutathione Peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinoma," *Free Radical Research*, vol. 41, no. 6, pp. 681–687, 2007.

[33] C. M. Woolston, A. Al-Attar, S. J. Storr, I. O. Ellis, D. A. L. Morgan, and S. G. Martin, "Redox protein expression predicts radiotherapeutic response in early-stage invasive breast cancer patients," *International Journal of Radiation Oncology Biology Physics*, vol. 79, no. 5, pp. 1532–1540, 2011.

[34] C. B. Ambrosone, "Oxidants and antioxidants in breast cancer," *Antioxidants and Redox Signaling*, vol. 2, no. 4, pp. 903–917, 2000.

[35] S. Perwez Hussain, M. H. Hollstein, and C. C. Harris, "p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment," *Annals of the New York Academy of Sciences*, vol. 919, pp. 79–85, 2000.